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Abstract 
The FDA has advocated for increasing awareness of histoplasmosis for patients undergoing TNF 
blockers as delay in diagnosis can lead to a poor outcome.1 Laryngeal histoplasmosis is a rare entity that 
should be part of the differential diagnosis in patients receiving immune suppression for Crohn’s disease. 
Patients with laryngeal histoplasmosis often report hoarseness, mucosal ulcerations, dysphagia, and 
odynophagia. We present a series of two cases of laryngeal histoplasmosis in patients with Crohn’s. 
These cases illustrate the high index of suspicion required to make the diagnosis of laryngeal 
histoplasmosis, especially in the Midwestern United States. Diagnosis is made quickly and cost-
effectively with proper staining. Delayed diagnosis may lead to dissemination, increased morbidity, and 
mortality. 
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Introduction
Involvement of the larynx in Crohn’s disease 
is rarely described, but may be associated with 
symptoms such as dysphonia, dysphagia and 





formation, laryngeal edema, and vocal 
fold hypomobility.1,2 With biologics like 
Humira (adalimumab) leading to improved 
management of Crohn’s disease, side effects 
of immune suppression should be considered 
in the differential diagnosis for patients 
with symptoms in the upper aerodigestive 
tract. The FDA has advocated for increasing 
awareness of histoplasmosis for patients 
undergoing treatment with TNF blockers 
as delay in diagnosis can lead to a poor 
outcomes.3 
Histoplasmosis, a granulomatous disease 
caused by the intracellular organism 
Histoplasma capsulatum, is the most 
commonly diagnosed endemic mycosis in 
the United States, and is most prevalent in 
the Ohio and Mississippi River Valleys.3,4 
Laryngeal histoplasmosis rarely presents 
as an isolated primary lesion and is 
more often associated with disseminated 
histoplasmosis. Due to its low prevalence, 
laryngeal histoplasmosis is often not 
included in the differential diagnosis of 
many clinicians. In the absence of other 
symptoms, such as laryngeal lesions 
associated with histoplasmosis, it may 
easily be confused with laryngeal Crohn’s, 
carcinoma or tuberculosis.4,5 We report two 
cases of laryngeal histoplasmosis in patients 
with Crohn’s disease receiving adalimumab 
therapy and discuss the clinical presentation, 
diagnosis, and management of this disease. 
Consent was obtained for usage of patient 
photographs. 
Case
Two individual patients presented to our 
clinic for evaluation of new onset voice 
changes with associated odynophagia and 
dysphagia. Upon evaluation, it was noted that 
both patients were on immunosuppression 
medication including Humira (adalimumab) 
for Crohn’s disease and both were non-
smokers. 
The endoscopic evaluation revealed laryngeal 
lesions suspicious for malignancy with 
diffuse laryngeal disease with ulceration 
and thickening of the supraglottic larynx 
(Figure 1A). Biopsy of both patients was 
performed to rule out laryngeal malignancy. 
One patient was diagnosed after Gomori 
Methenamine Silver Stain showed the 
presence of intracellular organisms consistent 
with histoplasmosis (Figure 2). The second 
patient’s diagnosis was delayed until bowel 
resection pathology showed disseminated 
histoplasmosis. The laryngeal slides were re-
reviewed in light of the bowel resection and 
were indeed positive for fungal elements that 
were not diagnosed on the original pathology 
slides. Both patients were seen by Infectious 
Disease specialists and received antifungal 
therapy in addition to discontinuation of 
Humira, ultimately leading to resolution 
of their symptoms. Follow up endoscopic 
examination after two months of therapy 
showed marked improvement of laryngeal 
lesions (Figure 1B), and complete resolution 
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months for the second.
Discussion
Laryngeal histoplasmosis is a relatively 
rare presentation of this mycosis and can 
widely vary in its presentation. Typically, 




and can subsequently spread hematologically 
to other organ systems. Although the 
involvement of the larynx is usually 
associated with disseminated disease, there 
have been cases reported in the literature of 
primary laryngeal histoplasmosis.6
The majority of infected patients are 




illness which resolves without treatment. 
Immunocompromised patients, however, 
have an increased risk of disseminated 
disease, which can progress to fatality if 
left untreated.7 Of note, both patients in 
this series were receiving adalimumab for 
immunosuppressive therapy at the time of 
diagnosis. 
In patients taking TNF blockers, 
histoplasmosis is the most common invasive 
fungal infection, and is a more common cause 
of serious infections than tuberculosis.3!

	
for developing protective immunity against 
Histoplasma capsulatum, and inhibiting this 
cytokine can lead to macrophage dysfunction.8 






A: Pre-antifungal therapy. Moderately edematous and erythematous supraglottic larynx with irregular 
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to present with pneumonia or other pulmonary 
symptoms and/or signs of progressive 
disseminated histoplasmosis, but may also 
present with symptoms including skin 
necrosis,3 or bowel perforation and laryngeal 
lesions as seen in our patients.
Sonkhya et al. reported that the most common 
primary laryngeal lesions were located on 
the false cords and aryepiglottic folds, with 
an endophytic pattern of growth. However, 
an exophytic pattern of growth has also been 
reported, as have locations involving the 
laryngeal surface of the epiglottis, the vocal 
cords, cricoid region, and supraglottic region.6
The diagnosis of laryngeal histoplasmosis is 
challenging secondary to the varied physical 
presentation of the lesions, and their similarity 
to malignancy. While suspicion must be high 
in an immunocompromised patient, the key 

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It is imperative to biopsy the lesions 
and communicate your suspicions to the 
examining pathology, as Grocott and Gomori 
silver staining can distinguish the yeast forms. 
Therapy for histoplasmosis varies according 
to the immune status of the patient, as well 
as the extent and severity of the disease. 
Intravenous Amphotericin B for 7-10 days 
followed by oral Itraconazole for 9-12 months 
is the treatment of choice for disseminated 
disease with pulmonary involvement.9 It is not 
currently recommended to routinely screen for 
histoplasma antigen or to treat patients taking 
TNF blockers prophylactically with anti-
fungal therapy.3
Conclusion
Laryngeal histoplasmosis is an unusual 
presentation of this dimorphic fungus, one 
that can easily be mistaken for malignancy 

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to have a high index of suspicion of this 
disease, especially in immunocompromised 
patients and in endemic areas, so that 
appropriate testing is performed. Indeed, 
$	
present in patients with Crohn’s disease 
undergoing surveillance endoscopy who are 
on treatment with Humira (adalimumab). 
Delay may lead to further dissemination of 
the disease, resulting in increased morbidity 
and mortality. It is especially important 
to consider this diagnosis if the patient 
is immunocompromised and pathologic 
examination has ruled out malignancy. 
https://doi.org/10.32873/unmc.dc.gmerj.2.1.009 
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Figure 2. Gomori Methamine Stain 400x showing fungal-like yeast forms.
